Introduction: Phase 1b GO30140 and phase 3 IMbrave150 studies evaluated first-line
atezolizumab+ bevacizumab for unresectable hepatocellular carcinoma (HCC). Here, we …

Abstract Background & Aims Thrombocytosis is associated with more aggressive tumour
biology in many malignancies. There are limited data in patients with hepatocellular …

Aberrant specific N-glycosylation, especially the increase in fucosylation on specific peptide
sites of serum proteins have been investigated as potential markers for diagnosis of …

Autoimmune liver diseases are attributed to a complex interplay of biologic, acquired, and
environmental factors. Increased prevalence, later stage at presentation, worse response to …

Background Preliminary studies have suggested that soluble programmed death-1 (sPD-1)
and soluble programmed cell death ligand-1 (sPD-L1) have prognostic implications in many …

Worldwide, nonalcoholic fatty liver disease (NAFLD) has reached epidemic proportions and
in parallel, hepatocellular carcinoma (HCC) has become one of the fastest growing cancers …

Background Racial/ethnic disparities in prognosis have been reported in patients with
hepatocellular carcinoma (HCC); however, few studies have evaluated racial/ethnic …

Introduction Immigrants comprise a considerable proportion of those diagnosed with
hepatocellular carcinoma (HCC) in the United States. Nativity or birthplace affects incidence …

Introduction Pernicious health disparities have been reported in patients with hepatocellular
carcinoma (HCC). Few tools exist to screen patients in order to facilitate educational and …

Racial, ethnic, and sex-based healthcare disparities have been documented for the past
several decades. Nonetheless, disparities remain firmly entrenched in our care delivery …